Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 11/20 | 0.37 |
| ▸ | AKT1S1 | Q96B36 | 4/20 | 0.37 |
| ▸ | NNMT | P40261 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11987587 | 0.89 | HTR2C (0.43) | HTR2AHTR2CHTR2BPARP1NNMT | |
| SCHEMBL13302581 | 0.82 | HTR2C (0.45) | UHRF1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL17041865 | 0.78 | UHRF1 (0.55) | UHRF1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL797188 | 0.76 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL23089693 | 0.73 | UHRF1 (0.41) | UHRF1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL22337366 | 0.73 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL580764 | 0.73 | UHRF1 (0.41) | UHRF1PARP1AKT1S1NNMT | |
| SCHEMBL18542965 | 0.73 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL23085984 | 0.73 | UHRF1 (0.41) | UHRF1PARP1AKT1S1NNMT | |
| SCHEMBL16196456 | 0.73 | UHRF1 (0.41) | UHRF1PARP1AKT1S1NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-01-21 | — | — | US | disclosed |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3670506-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | Incyte Holdings Corporation (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-02-06 | — | — | US | disclosed |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-09-05 | — | — | US | disclosed |
| US-9580443-B2 | Heterocyclic derivatives as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | UHRF1 1262/4885HTR2A 3673/4885HTR2C 3463/4885 |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | UHRF1 1262/4885HTR2A 3673/4885HTR2C 3463/4885 |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | UHRF1 3917/4885HTR2A 2096/4885HTR2C 2824/4885 |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | UHRF1 4010/4885HTR2A 3904/4885HTR2C 4020/4885 |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | UHRF1 1539/4885HTR2A 3477/4885HTR2C 3150/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | UHRF1 3639/4885HTR2A 3732/4885HTR2C 3791/4885 |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | UHRF1 1262/4885HTR2A 3673/4885HTR2C 3463/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | UHRF1 4010/4885HTR2A 3904/4885HTR2C 4020/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | UHRF1 1262/4885HTR2A 3673/4885HTR2C 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.